Frontiers in Cardiovascular Medicine (Jun 2023)

Abnormal plasma ceramides refine high-risk patients with worsening heart failure

  • Lu Ren,
  • Lu Ren,
  • Fengjuan Li,
  • Fengjuan Li,
  • Xin Tan,
  • Xin Tan,
  • Yangkai Fan,
  • Yangkai Fan,
  • Bingbing Ke,
  • Yixin Zhang,
  • Hongfeng Jiang,
  • Hongfeng Jiang,
  • Lixin Jia,
  • Lixin Jia,
  • Lixin Jia,
  • Yuan Wang,
  • Yuan Wang,
  • Jie Du,
  • Jie Du

DOI
https://doi.org/10.3389/fcvm.2023.1185595
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundWorsening heart failure (WHF) is a heterogeneous clinical syndrome with poor prognosis. More effective risk stratification tools are required to identify high-risk patients. Evidence suggest that aberrant ceramide accumulation can be affected by heart failure risk factors and as a driver of tissue damage. We hypothesized that specific ceramide lengths and ratios serve as biomarkers for risk stratification in WHF patients by reflecting pathological changes of distinct organ dysfunctions.MedthodsWe measured seven plasma ceramides using liquid chromatography-mass spectrometry (LC-MS) in 1,558 patients, including 1,262 participants in retrospective discovery set and 296 WHF patients in prospective validation set in BIOMS-HF study (Registry Study of Biomarkers in Heart Failure). Univariable and multivariable logistic regression models were constructed to identify associations of ceramides with organ dysfunctions.ResultsWe constructed three ceramide-based scores linked independently to heart, liver, and kidney dysfunction, with ceramides and ratios included in each score specifying systemic inflammation, chronic metabolic disorder, and water-sodium retention. The combined ceramide heart failure score (CHFS) was independently associated with adverse outcomes [Hazard Ratio, 2.80 (95% CI: 1.78–4.40; P < 0.001); 2.68 995% CI: 1.12–6.46; P = 0.028)] and improved the predictive value of Acute Decompensated Heart Failure National Registry score and BNP [net reclassification index, 0.34 (95% confidence interval, CI: 0.19–0.50); 0.42 (95% CI: 0.13–0.70)] in the discovery and validation set, respectively. Lower BNP levels, but higher CHFS had the highest hazard of future adverse events in WHF patients.ConclusionAbnormal plasma ceramides, associated with heart and peripheral organ dysfunctions, provide incremental prognostic information over the ADHERE score and brain natriuretic peptide concentration for risk stratification in WHF patients. This may facilitate the reclassification of high-risk patients in need of aggressive therapeutic interventions.

Keywords